WebJun 1, 2016 · Potential Treatment for SRSE. Research leading up to the ongoing phase 3 trial of SAGE-547, a potential drug for super-refractory status epilepticus, was presented at … WebApr 25, 2024 · It currently trades at a market cap of $2.74 billion, based primarily on the perceived value of its phase 3 drug candidate, SAGE-547, in development for super …
EX-99.1
WebJul 29, 2024 · Patients and investigators were masked to treatment assignments. The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score … WebIn the former, domination is abhorred; in the latter it is ines- capable, which changes dramatically the functioning of the line of command.” ([20], pp. 55-56) A central notion present in the literature is that management control has shifted from what is called techno- cratic control into diverse forms of normative control [21]; Foucauldian ideology … heartwater tick
Trial of SAGE-217 in Patients with Major Depressive Disorder
WebAug 17, 2015 · CAMBRIDGE, Mass., Aug. 17, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE) today announced it has treated the first patient enrolled in the STATUS … WebDec 4, 2024 · Background: The anticipatory prescribing of injectable medications to provide end-of-life symptom relief is an established community practice in a number of countries. The evidence base to support this practice is unclear. Aim: To review the published evidence concerning anticipatory prescribing of injectable medications for adults at the end of life … WebJul 29, 2024 · BACKGROUND: Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones. This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive allosteric modulator of γ-aminobutyric acid … heartwater symptoms